Safety and efficacy of insulin degludec/liraglutide (ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the safety and efficacy of insulin degludec/liraglutide (ID egLira), a novel combination product, as add‐on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy. Methods: In this 26‐week, double‐blind trial, adults with Type 2 diabetes [HbA 1c 53–75 mmol/mol (7.0–9.0%)] were randomized to ID egLira (n = 289) or placebo (n = 146) as add‐on to pre‐trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0–6.0 mmol/l. Treatment initiation was at 10 dose steps, and maximum dose was 50 dose steps (50 units insulin degludec/1.8 mg liraglutide). Results: The mean HbA 1c decreased from 63 mmol/mol (7.9%) to 46 mmol/mol (6.4%) with ID egLira and to 57 mmol/mol (7.4%) with placebo [estimated treatment difference –11 mmol/mol (95% CI –13; –10) or –1.02% (95% CI –1.18; –0.87); P < 0.001]. The HbA 1c target of 53 mmol/mol (<7%) was achieved by 79.2% of participants in the ID egLira group vs 28.8% in the placebo group [estimated odds ratio 11.95 (95% CI 7.22; 19.77); P < 0.001]. Mean weight change was +0.5 kg with ID egLira vs –1.0 kg with placebo [estimated treatment difference 1.48 kg (95% CI 0.90; 2.06); P < 0.001]. Confirmed hypoglycaemia occurred in 41.7 and 17.1% of ID egLira‐ and placebo‐treated participants, respectively, with rates of 3.5 vs 1.4 events/patient‐years of exposure [estimated rate ratio 3.74 (95% CI 2.28; 6.13); P < 0.001]. ID egLira was generally well tolerated. The rates of serious adverse events were 20.3 and 8.0 per 100 patient‐years of exposure with ID egLira and placebo, respectively, without obvious patterns in the type of events. Conclusions: ID egLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Self-citationAssessing the potential for α-glucosidase inhibitors in prediabetic states
Holman, R. R. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00038-2 · Cited by 197
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Self-citationOnishi, Y., Iwamoto, Y., Yoo, S. J., Clauson, P., Tamer, S. C., & Park, S. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12102 · Cited by 102
Cited by
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Linjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0218-3 · Cited by 136
Self-citationAroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
Metadata
- Authors
- Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., & the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2016-10-07
- Volume
- 34
- Issue
- 2
- Pages
- 189-196
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2516820342
- Cited by
- 109
- References
- 9
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.